Vivos Scientific

Vivos Inc. is a clinical-stage radiation oncology medical device company pioneering Precision Radionuclide Therapy (PRnT) for both human and veterinary applications. The company's core technology is a proprietary Yttrium-90-based injectable hydrogel platform designed to deliver localized, high-dose beta radiation directly inside solid tumors while protecting surrounding healthy tissue. Its lead human product, RadioGel, has received FDA Breakthrough Device designation and FDA Investigational Device Exemption (IDE) approval to begin a first-in-human clinical feasibility study for non-resectable papillary thyroid carcinoma. Its veterinary counterpart, IsoPet, is commercially available and actively used across certified clinics in the United States to treat canine, feline, and equine cancers.